|
Re: Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial
|
6
|
Resverlogix Corp.
|
May 15, 2017 10:37AM
|
|
Re: Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
|
6
|
Resverlogix Corp.
|
May 30, 2017 02:52PM
|
|
Re: Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
|
2
|
Resverlogix Corp.
|
May 30, 2017 12:31PM
|
|
Re: Resverlogix Reasonable Expectations
|
3
|
Resverlogix Corp.
|
Feb 11, 2016 01:59PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
8
|
Resverlogix Corp.
|
Jun 22, 2020 07:39AM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
4
|
Resverlogix Corp.
|
Jun 22, 2020 08:32AM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
4
|
Resverlogix Corp.
|
Jun 22, 2020 09:28AM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
8
|
Resverlogix Corp.
|
Jun 22, 2020 09:32AM
|
|
Re: Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial
|
3
|
Resverlogix Corp.
|
Jun 12, 2019 11:51AM
|
|
Re: Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
|
1
|
Resverlogix Corp.
|
May 24, 2018 08:41AM
|
|
Re: Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
|
6
|
Resverlogix Corp.
|
May 25, 2018 10:47AM
|
|
Re: Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
|
3
|
Resverlogix Corp.
|
May 25, 2018 02:16PM
|
|
Re: Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
|
3
|
Resverlogix Corp.
|
May 26, 2018 11:17AM
|
|
Re: Resverlogix Provides Groundbreaking Results...
|
1
|
Resverlogix Corp.
|
Jan 23, 2017 11:22AM
|
|
Re: Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in PAH
|
2
|
Resverlogix Corp.
|
Mar 18, 2019 01:08PM
|
|
Re: Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
|
7
|
Resverlogix Corp.
|
Sep 04, 2018 08:58AM
|
|
Re: Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
|
3
|
Resverlogix Corp.
|
Sep 04, 2018 01:01PM
|
|
Re: Resverlogix presenting at Vascular Discovery 2019 next week
|
3
|
Resverlogix Corp.
|
May 11, 2019 11:18AM
|
|
Re: Resverlogix presenting at Vascular Discovery 2019 next week
|
3
|
Resverlogix Corp.
|
May 14, 2019 05:23PM
|
|
Re: Resverlogix presenting at Vascular Discovery 2019 next week
|
6
|
Resverlogix Corp.
|
May 11, 2019 01:28PM
|
